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ABSTRACT Human cytomegalovirus (HCMV) can cause significant disease in immu-
nocompromised patients, and treatment options are limited by toxicities. CSJ148 is a
combination of two anti-HCMV human monoclonal antibodies (LJP538 and LJP539)
that bind to and inhibit the functions of viral HCMV glycoprotein B (gB) and the
pentameric complex, consisting of glycoproteins gH, gL, UL128, UL130, and UL131.
In this phase 2, randomized, placebo-controlled trial, we evaluated the safety and ef-
ficacy of CSJ148 for prophylaxis of HCMV in patients undergoing allogeneic hemato-
poietic stem cell transplantation. As would be expected in the study population, all
the patients (100%) reported at least one treatment-emergent adverse event. There
were 22 deaths during this study, and over 80% of the patients receiving placebo or
CSJ148 developed at least one adverse event of grade 3 or higher severity. No sub-
ject who received antibody developed a hypersensitivity- or infusion-related reac-
tion. CSJ148-treated patients showed trends toward decreased viral load, shorter
median duration of preemptive therapy, and fewer courses of preemptive therapy.
However, the estimated probability that CSJ148 decreases the need for preemptive
therapy compared to placebo was 69%, with a risk ratio of 0.89 and a 90% credible
interval of 0.61 to 1.31. The primary efficacy endpoint was therefore not met, indi-
cating that CSJ148 did not prevent clinically significant HCMV reactivation in recipi-
ents of allogeneic hematopoietic cell transplants. (This study has been registered at
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Human cytomegalovirus (HCMV) infection is common, with approximately 60% ofthe population worldwide infected (1). Most infections are mild or asymptomatic,
but clinically significant HCMV disease and complications can occur in immuno-
compromised individuals. These individuals include hematopoietic cell transplant
(HCT) and solid organ transplant recipients, people infected with human immuno-
deficiency virus (HIV), and newborns exposed to HCMV in utero. Everyone previously
infected with HCMV is at risk for HCMV reactivation and, if immunocompromised,
significant disease.
Among HCT recipients, HCMV infection is associated with increased morbidity and
mortality, even in the preemptive therapy era (2). Pneumonia is the most serious HCMV
disease among HCT recipients, with mortality exceeding 50% (3). Other HCMV mani-
festations include gastroenteritis, hepatitis, retinitis, and encephalitis (4). In addition,
HCMV infection and its treatment are associated with (secondary) graft failure, in-
creased incidence of bacterial and fungal infections, and potentially increased inci-
dence of graft-versus-host disease (GVHD). In the absence of prophylaxis, the majority
of HCMV-seropositive allogeneic HCT recipients develop HCMV reactivation after trans-
plantation, and approximately 10 to 15% develop HCMV disease if preemptive therapy
is not given (2).
HCMV antivirals include ganciclovir, valganciclovir, foscarnet, and cidofovir. These
drugs are effective at preventing and treating HCMV reactivation and disease but are
associated with significant toxicities, such as renal toxicity and electrolyte disturbances.
Bone marrow toxicity limits the use of these agents for prophylaxis in patients under-
going HCT until after engraftment (4), and up to 15% of patients develop significant
HCMV infection and disease during this preengraftment period (5–7). Letermovir, an
HCMV-specific terminase complex inhibitor with an improved safety profile, has re-
cently become available for prevention of HCMV infection after HCT (8) and can be used
safely during the early preengraftment period. However, letermovir is associated with
patient compliance issues, drug-drug interactions, low-grade adverse events, and
breakthrough HCMV infections.
CSJ148 consists of two anti-HCMV human monoclonal antibodies (LJP538 and
LJP539) (9) and offers the potential to be a safe and well-tolerated alternative to
currently available therapies for the prevention and treatment of HCMV. Each antibody
binds to and inhibits the function of essential viral glycoproteins; LJP538 binds to
glycoprotein B (gB), and LJP539 binds to the pentameric complex (consisting of
glycoproteins gH, gL, UL128, UL130, and UL131). CSJ148 neutralizes HCMV infection of
all the cell types tested by blocking both initial infection and the subsequent cell-to-cell
spread of virus (9).
In healthy volunteers, CSJ148 is safe and well tolerated (10). Adverse events
and laboratory abnormalities occurred sporadically, with similar incidences be-
tween antibody and placebo groups and without any apparent relationship to dose.
After intravenous administration, both LJP538 and LJP539 demonstrated typical
human IgG1 pharmacokinetic properties, with slow clearances, limited volumes of
distribution, and long terminal half-lives (10). Based on its safety profile, CSJ148 has
the potential to be used prior to engraftment to prevent HCMV infection and
disease.
The aim of this phase 2 study (ClinicalTrials.gov no. NCT02268526; EudraCT no.
2017-002047-15) was to assess the clinical safety and efficacy of CSJ148 in preventing
HCMV infection in HCT recipients during the first 98 days after transplantation.
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RESULTS
Patients. Six patients were enrolled in cohort 1, and all received the planned four
doses of CSJ148 (Table 1); five completed the study. In cohort 2, 80 patients were
enrolled, and 54 patients (38 in the CSJ148-treated group and 16 in the placebo-treated
group) completed the study. The most common reasons for discontinuation were death
(12; 14.0%), subject’s decision (10; 11.6%), and adverse event (3; 3.5%). The most
common reasons for exclusion from the pharmacodynamics (PD) analysis sets were use
of medication with anti-HCMV activity prior to meeting a primary endpoint, withdrawal
from the study or death prior to meeting the primary endpoint or day 99 (whichever
came first), and missing a study drug dose prior to meeting the primary endpoint (see
the supplemental material).
Baseline demographics and other characteristics were generally comparable be-
tween CSJ148-treated and placebo-treated patients (Table 2). All the patients were
HCMV seropositive before transplantation. However, the median age of CSJ148-treated
patients (56 years) was greater than that of the placebo-treated patients (44 years). In
addition, the CSJ148-treated patients were predominantly white, while the placebo-
treated patients were predominantly Asian. Based on differences of at least 10%,
potentially relevant differences in baseline transplant characteristics included more
CSJ148-treated patients receiving a graft from unrelated donors or from HCMV-
seronegative donors and a marrow graft, while more placebo-treated patients received
T cell-depleted grafts and peripheral blood stem cells. The majority of patients received
a graft from a complete-match donor (80% and 71.4% in CSJ148-treated and placebo-
treated patients, respectively); haploidentical donors were used in 23.8% of CSJ148-
treated and 15.4% of placebo-treated patients.
Efficacy. Efficacy was evaluated by monitoring clinical outcomes and HCMV loads. The
primary endpoint was the proportion of patients who required preemptive anti-HCMV
therapy or treatment for HCMV disease. In the full analysis set, 37% of patients who
received CSJ148 and 43% of those receiving placebo required preemptive therapy. The
Bayesian model using a historical placebo prior shows a reduction of approximately 11%
(risk ratio, 0.89; 90% confidence interval [CI], 0.61 to 1.31). The estimated probability that
CSJ148 therapy decreases the need for preemptive therapy compared to placebo was 69%.
Similar trends were observed in all analysis populations examined (Table 3).
The median viral load at the initiation of preemptive therapy for CSJ148-treated
patients was 1,914 copies/ml (range, 120 to 45,430 copies/ml) compared with 5,555
copies/ml (range, 875 to 15,620 copies/ml) for placebo-treated patients. One subject
TABLE 1 Patient disposition
Parameter
Value [no. (%)]
Cohort 1, CSJ148 (n 6)
Cohort 2
Total CSJ148 (n 65)CSJ148 (n 59) Placebo (n 21
Patients
Completed 5 (83.3) 38 (64.4) 16 (76.2) 43 (66.2)
Discontinued 1 (16.7) 21 (35.6) 5 (23.8) 22 (33.8)
Main cause of discontinuation
Adverse event(s) 0 (0.0) 2 (3.4) 1 (4.8) 2 (3.1)
Death 1 (16.7) 11 (18.6) 0 (0.0) 12 (18.5)
Protocol deviation 0 (0.0) 1 (1.7) 0 (0.0) 1 (1.5)
Physician’s decision 0 (0.0) 0 (0.0) 1 (4.8) 0 (0.0)
Subject’s decision 0 (0.0) 7 (11.9) 3 (14.3) 7 (10.8)
Analysis sets
Safety and full analysis 6 59 21 65
PK 6 59 65
PD 42 17 42
Combined PD (cohorts 1 and 2) 5 42 17 47
Modified PD (cohort 2 only) 36 16 36
Combined modified PD (cohorts 1 and 2) 5 36 16 41
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who received CSJ148 had HCMV loads below the limit of quantification. For patients
who had HCMV loads of 1,000 copies/ml at the initiation of the first course of
preemptive therapy (n 29), 13/20 (65%) CSJ148-treated patients and 6/9 (67%)
placebo-treated patients achieved viral loads below the lower limit of quantification
before the end of treatment on day 99. The median time to achieve a viral load below
the lower limit of quantification after the first course of preemptive therapy was shorter
TABLE 2 Summary of demographic and baseline transplant characteristics by treatment
Parametera
Value
Placebo
(n 21)
Total active
CSJ148 (n 65)
Total active and
placebo (n 86)
Age (yr)
Median 44.0 56.0 55.0
Range 22, 67 22, 76 22, 76
Sex [no. (%)]
Male 15 (71.4) 40 (61.5) 55 (64.0)
Female 6 (28.6) 25 (38.5) 31 (36.0)
Race [no. (%)]
White 7 (33.3) 36 (55.4) 43 (50.0)
Asian 14 (66.7) 25 (38.5) 39 (45.3)
Other 0 (0.0) 4 (6.2) 4 (4.7)
BMIb (kg/m2)
Median 23.7 25.7 24.8
Range 19, 29 19, 33 19, 33
Donor type [no. (%)]
Not related 7 (33.3) 36 (55.4) 43 (50.0)
Related 14 (66.7) 29 (44.6) 43 (50.0)
Stem cell source [no. (%)]
Bone marrow 1 (4.8) 11 (16.9) 12 (14.0)
Peripheral blood 20 (95.2) 52 (80.0) 72 (83.7)
Cord blood 0 (0.0) 2 (3.1) 2 (2.3)
Transplant type [no. (%)]
Match 15 (71.4) 52 (80.0) 67 (77.9)
Haploidentical 5 (23.8) 10 (15.4) 15 (17.4)
Other 1 (4.8) 3 (4.6) 4 (4.7)
Donor HCMV seropositive [no. (%)]
No 5 (23.8) 22 (33.8) 27 (31.4)
Yes 15 (71.4) 41 (63.1) 56 (65.1)
Unknown 1 (4.8) 2 (3.1) 3 (3.5)
Conditioning regimen [no. (%)]
Nonmyeloablative 11 (52.4) 39 (60.0) 50 (58.1)
Myeloablative 10 (47.6) 26 (40.0) 36 (41.9)
T cell depletion [no. (%)]
No 15 (71.4) 61 (93.8) 76 (88.4)
Yes 6 (28.6) 4 (6.2) 10 (11.6)
aAnalysis set, all patients.
bBMI, body mass index.
TABLE 3 Summary of the posterior distribution of the proportion of patients that required preemptive anti-HCMV therapy up to visit
day 99
Set CSJ148 [no. (%)] Placebo [no. (%)]
Estimated CSJ148/placebo median
risk ratio (90% CI)
Posterior probability of
risk ratio<1
Full analysis 24/65 (36.9) 9/21 (42.9) 0.891 (0.606,1.305) 0.694
Combined PD 23/47 (48.9) 9/17 (52.9) 0.926 (0.615, 1.524) 0.611
Combined modified PD 17/41 (41.5) 8/16 (50.0) 0.829 (0.515, 1.449) 0.722
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in CSJ148-treated (median, 20 days; range, 5 to 36 days) than in placebo-treated
(median, 30 days; range, 15 to 52 days) patients. The median time to start of therapy
was 97.6 days (95% CI, 76.5 days [upper limit not calculated]) and 80.6 days (95% CI,
45.5 days [upper limit not calculated]) among CSJ148-treated (n 24) and placebo-
treated (n 9) patients, respectively (log rank P value, 0.282) (Fig. 1).
Although not statistically significant (P 0.335), the median duration of preemptive
therapy tended to be shorter in CSJ148-treated (35 days) than in placebo-treated
(39 days) patients. The numbers of courses of preemptive therapy required were 2 and
3 for CSJ148- and placebo-treated patients, respectively.
Eight patients developed HCMV disease (including the cases occurring after day 99),
with more occurring in CSJ148-treated patients (7/65; 11%) than in placebo-treated
patients (1/21; 5%). All the cases, except one diagnosed in a CSJ148-treated patient, had
tissue evidence of HCMV disease based on histology or detection of viral DNA in the
target organs. Five of the patients receiving CSJ148 developed HCMV disease prior to
the end-of-treatment visit on day 99; all five had developed GVHD prior to the diagnosis
of HCMV disease. During the follow-up period, two CSJ148-treated and one placebo-
treated patients developed HCMV disease; none had prior GVHD.
Exploratory post hoc analyses using the combined PD analysis set were performed
to determine if the lack of efficacy could be explained in part by confounding factors.
Although this was a post hoc assessment and the sample size was too small to draw
definitive conclusions, potentially relevant associations of three baseline factors and
one postenrollment factor with the primary outcome were noted (based on a Cochran-
Mantel-Hazard [CMH] test; P  0.300) (Table 4). The baseline factors were receiving a
myeloablative versus a nonmyeloablative conditioning regimen (P 0.146), receiving a
mismatched versus a matched transplant (P 0.009), and receiving stem cells from an
unrelated donor versus a related donor (P 0.039). The postenrollment factor was
development of acute GVHD (P 0.001). Other factors examined but found to be
unassociated with the primary outcome (P 0.300) included donor HCMV serostatus,
T cell depletion of the graft, and development of chronic GVHD. The source of the stem
cells was also considered but not examined because no placebo-treated patient
received cord blood.
Three of the four potentially confounding factors showed a trend toward association
with the treatment group. Proportionally more CSJ148-treated patients received a
transplant from an unrelated donor (P 0.254) and developed acute GVHD (P 0.160).
Proportionally more patients who received placebo received a myeloablative condi-
tioning regimen (P 0.272) (Table 5).
Pharmacokinetics. Following intravenous (i.v.) administration of CSJ148, LJP538,
and LJP539, serum concentrations of both antibodies increased rapidly and reached the
maximum concentration around the end of infusion. Serum concentrations decreased
quickly after the infusion ended, with a rapid distribution phase followed by a much
slower terminal elimination phase. Concentrations of both LJP538 and LJP539 increased
with each subsequent dose. The mean accumulation ratios from first to last dose were
FIG 1 Cumulative survival free of the need to start preemptive therapy for HCMV. Patients treated with
CSJ148 and those receiving placebo are shown. The time to start of preemptive therapy was defined as
the number of days between the initial dose of study drug and (i) the start of preemptive therapy, (ii) the
development of HCMV disease, or (iii) death due to HCMV disease. The log rank P value was 0.282 for
comparison of the two curves.
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1.83 and 2.11 for LJP538 and LJP539, respectively. The mean terminal elimination
half-lives after the last dose were estimated to be 19.7 and 23.8 days for LJP538 and
LJP539, respectively. The absence of accelerated clearance during the long terminal
elimination phase suggests that significant levels of anti-drug antibodies had not
TABLE 4 Summary of associations between potential confounding factors and primary endpointa
Category Subcategory
Valueb
P valuec
CSJ148 (cohorts 1 and 2)
[n/N (%, 90% CI)]
Placebo (cohort 2)
[n/N (%, 90% CI)]
Total
[n/N (%)]
Postenrollment factors
Acute GVHD Yes 17/24 (71, 52–85) 4/5 (80, 34–99) 21/29 (72.4) 0.001
No 6/23 (26, 12–45) 5/12 (42, 18–68) 11/35 (31.4)
Chronic GVHD Yes 3/9 (33, 10–66) 2/4 (50, 10–90) 5/13 (38.5) 0.351
No 20/38 (53, 38–67) 7/13 (54, 29–78) 27/51 (52.9)
Baseline factors
Age 40 yr 20/41 (49, 35–63) 5/10 (50, 22–78) 25/51 (49.0) 0.818
40 yr 3/6 (50, 15–85) 4/7 (57, 23–87) 7/13 (53.8)
55 yr 11/24 (46, 28–64) 2/5 (40, 8–81) 13/29 (44.8) 0.483
55 yr 12/23 (52, 34–70) 7/12 (58, 32–82) 19/35 (54.3)
Conditioning regimen Myeloablative 14/20 (70, 49–86) 4/10 (40, 15–70) 18/30 (60.0) 0.146
Nonmyeloablative 9/27 (33, 19–51) 5/7 (71, 34–95) 14/34 (41.2)
Donor HCMV seropositive No 9/17 (53, 31–74) 3/5 (60, 19–92) 12/22 (54.5) 0.579
Yes 13/29 (45, 29–62) 6/11 (55, 27–80) 19/40 (47.5)
Donor type Not related 16/23 (70, 50–85) 2/5 (40, 8–81) 18/28 (64.3) 0.039
Related 7/24 (29, 15–48) 7/12 (58, 32–82) 14/36 (38.9)
Stem cell source Cord blood 0/1 (0.0) 0 0/1 (0.0) 0.328
Peripheral blood or bone marrow 23/46 (50, 37–63) 9/17 (53, 31–74) 32/63 (50.8)
T cell depletion Yes 0/2 (0.0) 3/4 (75, 25–99) 3/6 (50.0) 0.933
No 23/45 (51, 38–64) 6/13 (46, 22–71) 29/58 (50.0)
Transplant type Nonmatch 7/10 (70, 39–91) 5/5 (100, 55–100) 12/15 (80.0) 0.009
Match 16/37 (43, 29–58) 4/12 (33, 12–61) 20/49 (40.8)
aAnalysis set for the table, combined cohort 1 and 2 PD analysis set.
bn, number of subjects who reached the primary endpoint; N, number of patients with or without the given factor.
cP value based on CMH test stratified by treatment group.
TABLE 5 Summary of associations between potential confounding factors and treatment
Category Subcategory
Value [n/Na (%)]
P valuebCSJ148 (cohorts 1 and 2) Placebo (cohort 2)
Postenrollment factors
Acute GVHD Yes 24/47 (51.1) 5/17 (29.4) 0.160
No 23/47 (48.9) 12/17 (70.6)
Chronic GVHD Yes 9/47 (19.1) 4/17 (23.5) 0.732
No 38/47 (80.9) 13/17 (76.5)
Baseline factors
Age 40 yr 41/47 (87.2) 10/17 (58.8) 0.030
40 yr 6/47 (12.8) 7/17 (41.2)
55 yr 24/47 (51.1) 5/17 (29.4) 0.160
55 yr 23/47 (48.9) 12/17 (70.6)
Conditioning regimen Myeloablative 20/47 (42.6) 10/17 (58.8) 0.272
Nonmyeloablative 27/47 (57.4) 7/17 (41.2)
Donor HCMV seropositive No 17/46 (37.0) 5/16 (31.3) 0.769
Yes 29/46 (63.0) 11/16 (68.8)
Donor type Not related 23/47 (48.9) 5/17 (29.4) 0.254
Related 24/47 (51.1) 12/17 (70.6)
Stem cell source Cord blood 1/47 (2.1) 0/17 1.000
Peripheral blood or bone marrow 46/47 (97.9) 17/17 (100.0)
T cell depletion Yes 2/47 (4.3) 4/17 (23.5) 0.038
No 45/47 (95.7) 13/17 (76.5)
Transplant type Nonmatch 10/47 (21.3) 5/17 (29.4) 0.517
Match 37/47 (78.7) 12/17 (70.6)
an, number of subjects with or without the given factor; N, number of patients in each treatment group.
bBased on 2-sided Fisher’s exact test.
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developed during the study. Overall, the pharmacokinetic (PK) characteristics of both
LJP538 and LJP539 were typical of other human IgG1 antibodies and similar to that
seen in healthy volunteers.
In the 50 patients who received all four doses of CSJ148, the trough concentrations for
LJP538 and LJP539 were above the targeted efficacious concentrations (7.4 and 0.74g/ml
for LJP538 and LJP539, respectively). There was no relationship between trough concen-
trations and the need for preemptive anti-HCMV therapy (data not shown).
Safety. Significant morbidity and mortality are seen in patients undergoing HCT.
Consistent with this, all the patients (100%) in the safety analysis set reported at least
one treatment-emergent adverse event (see Table S1 in the supplemental material).
There were 22 deaths during the study. Over 80% of the patients receiving placebo or
CSJ148 developed at least one adverse event of grade 3 or higher severity, and the
majority developed at least one serious adverse event (46/65 [71%] for CSJ148 and
15/21 [71%] for placebo). The most frequently reported serious adverse events—acute
GVHD, febrile neutropenia, acute myeloid leukemia relapse, pneumonia, sepsis, and
acute kidney injury—are well-known direct complications of allogeneic HCT or the
subsequent increased susceptibility to disease.
The most common (50% incidence) treatment-emergent adverse events were nausea
(70% of total patients), diarrhea (65%), vomiting (61%), stomatitis (59%), and pyrexia (57%).
The incidences of grade 3 or higher adverse events were similar among CSJ148- and
placebo-treated patients. Based on an absolute difference of at least 10%, however, eight
adverse events occurred more frequently in CSJ148-treated patients (diarrhea, hyperten-
sion, dizziness, hemorrhoids, arthralgia, and noncardiac chest pain) and three occurred
more frequently in placebo-treated patients (stomatitis, upper abdominal pain, and neu-
tropenia). Only two adverse events were assessed as possibly related to the study drug
(fever and thrombocytopenia); both occurred in patients receiving placebo. The adverse
events occurring in more than 10% of either treatment group are listed in Table S1.
Fifty-eight of 65 (89.2%) CSJ148-treated and 17 of 21 (81.0%) placebo-treated
patients had at least one grade 3 or higher adverse event; the most common were
febrile neutropenia (30.2% of total patients), stomatitis (18.6%), and hypertension
(15.1%) (Table 6). In general, the incidences of all adverse events were similar for
CSJ148- and placebo-treated patients. Based on an absolute difference of at least 10%,
stomatitis and acute graft-versus-host disease occurred more frequently in CSJ148-
treated patients, and no adverse event occurred more frequently in placebo-treated
patients. As expected in the population studied, all the patients experienced hemato-
logic abnormalities. Among grade 4 hematologic adverse events with differences of at
least 10%, patients in the CSJ148-treated group had more frequent decreased platelet
counts (73.8% versus 61.9% in the placebo-treated group) and decreased neutrophil count
(53.8% versus 33.3% in the placebo-treated group), while grade 4 reduction in lymphocyte
count was more common in placebo-treated patients (100%) than CSJ148-treated patients
(84.6%) (see Table S2 in the supplemental material). Most clinical-chemistry abnormalities
TABLE 6 Incidence of grade 3 or higher adverse events (10%) by preferred term
Preferred term
Value [n (%)]
Placebo
(n 21)
Total active
CSJ148 (n 65)
Total active and
placebo (n 86)
Febrile neutropenia 5 (23.8) 21 (32.3) 26 (30.2)
Stomatitis 2 (9.5) 14 (21.5) 16 (18.6)
Hypertension 2 (9.5) 11 (16.9) 13 (15.1)
Diarrhea 3 (14.3) 8 (12.3) 11 (12.8)
Thrombocytopenia 3 (14.3) 8 (12.3) 11 (12.8)
Nausea 2 (9.5) 8 (12.3) 10 (11.6)
Acute GVHD 1 (4.8) 10 (15.4) 11 (12.8)
Neutropenia 2 (9.5) 7 (10.8) 9 (10.5)
Acute kidney injury 1 (4.8) 7 (10.8) 8 (9.3)
Anemia 3 (14.3) 5 (7.7) 8 (9.3)
Pneumonia 1 (4.8) 7 (10.8) 8 (9.3)
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were assessed as being part of the underlying disease process and transplantation, related
to a subsequent adverse event, or considered not clinically relevant.
Chronic GVHD (any grade) developed in 15% (10/65) of CSJ148-treated patients
compared with 19% (4/21) of placebo-treated patients (P  0.738). Acute GVHD
developed in 43% (28/65) of CSJ148-treated patients compared with 29% (6/21) of
placebo-treated patients (P  0.308). There were 10 (15%) CSJ148-treated patients and
1 (5%) placebo-treated patient with severe (grade 3 or higher) acute GVHD (including
intestine, liver, and skin). There were three (4.6%) CSJ148-treated patients who expe-
rienced severe chronic GVHD, and none in the placebo arm.
Twenty-two patients died during the study: 19/65 (29%) patients treated with
CSJ148 and 3/21 (14%) who received placebo. The median times to death following the
first dose of CSJ148 or placebo were 159 and 158 days, respectively. Of the 19 deaths
in the CSJ148-treated patients, 4 (6.2%) occurred during the treatment period (up to
day 99), 8 (12.3%) during follow-up (days 100 to 183), and 7 (10.8%) after the end-of-
study visit (after day 184). All deaths in placebo-treated patients occurred after the
end-of-treatment visit, with two (9.5%) deaths during the follow-up period and one
(4.8%) after the end-of-study visit. No patient deaths were suspected to be related to
the study drug, and all causes of death were consistent with those expected after
allogeneic HCT (see Table S3 in the supplemental material).
Exploratory post hoc analyses were performed among all patients in the safety set
to determine if the death rates could be explained in part by confounding factors.
Potentially relevant associations (based on a Cochran-Mantel-Hazard test P value of
0.3) were noted between mortality and age (55 versus 55 years of age; P  0.3),
transplant type (mismatched versus matched; P 0.01), and conditioning regimen
(myeloablative versus nonmyeloablative; P 0.01). Of these, only age 55 versus
55 years (P 0.10) showed an association with the treatment group based on a
Fisher’s exact test P value of 0.3; proportionally more patients 55 years of age
received CSJ148 (52.3%) than placebo (28.6%). Two additional factors reported to be
associated with mortality (11) also showed an association with the treatment group:
age 40 versus 40 years (P 0.01) and unrelated versus related donor type (P 0.3).
Proportionally more CSJ148-treated patients were 40 years of age (87.7% versus
51.7%) or received a transplant from an unrelated donor (55.4% versus 33.3%).
It was possible that CSJ148 might enhance tissue damage via antibody-dependent
cell-mediated cytotoxicity in the presence of HCMV replication. To investigate this, a
temporal analysis of deaths in relation to acute GVHD, clinically relevant HCMV infec-
tion, HCMV disease, and use of rescue anti-HCMV therapy was conducted among the
CSJ148-treated patients. Ten deaths occurred in patients without evidence of clinically
relevant HCMV infection or disease. Seven of these 10 patients were55 years old. No
clear temporal correlation with CSJ148 administration was identified, and only three
deaths occurred during the study treatment period. Nine deaths occurred in patients
with evidence of clinically relevant HCMV infection (n 4) or disease (n 5). Six of
these patients were55 years old. All nine of the patients received rescue anti-HCMV
therapy, and all but one had controlled HCMV infections (viral load 1,000 copies/ml)
prior to death. The one exception was a patient with a viral load of 2,948 copies/ml in
the week preceding death, down from a peak value of 1 million copies/ml after
receiving anti-HCMV therapy. This patient died during the treatment period from
atypical pneumonia after being diagnosed with GVHD and HCMV colitis.
All the subjects with HCMV disease and two subjects with HCMV infection had GVHD
diagnosed prior to or concurrently with HCMV. GVHD is a known risk factor for HCMV
disease. Taken together, these results indicate it was unlikely that CSJ148 exacerbated
end organ disease.
DISCUSSION
In this randomized phase 2 trial, in CSJ148-treated patients, the primary endpoint of
preventing HCMV infection or reactivation during the first 98 days after allogeneic HCT
was not met. The estimated probability that CSJ148 decreases the need for preemptive
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therapy compared to placebo was 69%. The risk ratio of 0.89 (90% CI, 0.61 to 1.31) was
not statistically significant, and the wide 90% CI of the risk ratio suggests significant
variability in the treatment effect. Secondary-efficacy results showed trends for a later
time to the start of preemptive therapy, a shorter duration of preemptive therapy, and
the need for fewer preemptive treatment courses. Although a higher rate of CSJ148-
treated patients (11%) than placebo-treated patients (5%) developed HCMV disease,
the difference was not statistically significant, and the small number of events pre-
cludes any definitive conclusions.
In the general allogeneic HCT population, the development of acute or chronic
GVHD and certain baseline transplant characteristics (HCMV-seropositive donor, my-
eloablative conditioning regimen, unrelated donor, mismatched donor, cord blood as
the source of the stem cells, and T cell depletion) are associated with a higher degree
of immunosuppression and are considered to increase the risk of HCMV reactivation
(12, 13). Additional exploratory post hoc analyses to determine if the lack of efficacy
could be explained in part by confounding factors showed that a potentially dispro-
portionate number of CSJ148-treated patients (51%) developed acute GVHD compared
with those who received placebo (29%), and the development of acute GVHD was
associated with a greater risk of requiring preemptive therapy for HCMV (71% versus
26% if acute GVHD did not occur) in CSJ148-treated patients. CSJ148-treated patients
(55%) were more likely to have received a graft from an unrelated donor than those
who received placebo (33%), and unrelated grafts appeared to also be associated with
a greater risk of requiring preemptive therapy for HCMV (70% versus 30% from related
donors) in CSJ148-treated patients. Because of the small trial size, imbalances in
relevant confounders between treatment arms may have occurred by chance. In this
trial, it appears that proportionally more patients treated with CSJ148 may have had
more potentially confounding attributes. It is possible that a combination of confound-
ers could have influenced the outcomes reported here. In addition, failure to demon-
strate efficacy with CSJ148 does not preclude the possibility that other antibody-
mediated therapies will not work.
In transplant patients and those with HIV disease and acquired immunodeficiency,
severe HCMV disease occurs almost exclusively in patients with profound T cell immune
deficiency (14). T cell responses correlate with protection and recovery from HCMV
disease. Infusion of HCMV-specific T cells has been used to restore cellular immunity
and to offer protection against HCMV disease (15, 16). Conversely, anti-HCMV antibod-
ies show only modest activity for preventing HCMV infection in transplant patients.
HCMV hyperimmune globulin is approved for the prevention of HCMV infection and
disease in solid organ transplantation, but not in HCT (17). Monoclonal IgG antibodies
show only modest effects in preventing HCMV infection after kidney transplantation,
but not after HCT (18). Together, these data suggest that the failure to meet the primary
endpoint could be due to an inability of CSJ148 to overcome the severe deficiencies in
T cell immunity seen among HCT patients in this study. However, CSJ148 did appear to
have anti-HCMV activity, and CSJ148 may be effective in lower-risk HCT populations or
in combination with anti-HCMV T cell immunity enhancers.
In contrast to preventing HCMV reactivation in transplant patients, prevention of
primary infection in utero might be possible with CSJ148. In HCMV congenital disease,
a predominant protective role of high-avidity IgG has been described. Preexisting IgG
reduced fetal transmission by 69% in pregnant women (19), and an anti-gH/gL mono-
clonal IgG was protective in a congenital guinea pig model (20). HCMV hyperimmune
globulin resulted in a statistically insignificant reduction in HCMV transmission to the
fetus compared with placebo (44% versus 30%) in 124 pregnant women with a primary
HCMV infection. This study, however, was designed to detect a 50% reduction in fetal
HCMV transmission, and the 33% relative risk reduction that was noted (P 0.13) may
be clinically relevant (21).
CSJ148 was well tolerated in the HCT patient population. Although there were
multiple serious adverse events reported in this population, the majority of events were
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consistent with those expected in patients undergoing HCT. The incidences of adverse
events and serious adverse events were similar between the treatment groups.
GVHD, a known complication of allogeneic HCT, was observed in higher proportion
in the CSJ148-treated patients. The reason for the higher rate in CSJ148-treated patients
is not clear, although these patients were older, and older age is a risk factor for acute
GVHD (22–26). Other imbalances in baseline characteristics may have also contributed
to the higher proportion of graft-versus-host disease observed in CSJ148-treated
patients. CSJ148-treated subjects had a lower proportion of T cell-depleted grafts than
placebo-treated subjects (6.2% and 28.6%, respectively) and a higher proportion of
nonrelated transplants (55.4% and 33.3%, respectively); both are risk factors for GVHD
(25, 27). Pooled immunoglobulin and monoclonal antibody preparations are not known
to cause or promote GVHD.
Overall mortality in the study population was consistent with the reported mortality
in HCT patients (29% to 66%) (11). All causes of death were consistent with those
expected after HCT, and none were suspected to be related to the study drug by the
investigators. A plausible direct causal relationship between CSJ148 treatment and
increased mortality was not identified, and the majority of deaths occurred after the
treatment period (during follow-up or after study completion). Although the sample
size is too small to draw definitive conclusions, post hoc analysis identified older age as
a potential confounder for mortality. Other factors potentially associated with mortality
examined included age (40 versus 40 years of age), donor type (unrelated versus
related), and presence of acute GVHD. Although none of them showed a trend toward
a potentially relevant association, all have been reported by others to increase the risk
of death (11, 28). Taken together, the data suggest a higher mortality rate among
CSJ148-treated patients than among placebo-treated patients being driven by these
patients having a higher mortality risk at baseline.
In conclusion, consistent with the experience in healthy volunteers, CSJ148 was well
tolerated and appears to have anti-HCMV activity. However, treatment did not prevent
clinically significant HCMV reactivation in HCMV-seropositive allogeneic HCT recipients.
MATERIALS AND METHODS
Study design. This phase 2 multicenter study was designed to evaluate the efficacy, safety, and
tolerability of CSJ148 in patients undergoing allogeneic HCT. The study comprised a screening period, a
baseline visit, a treatment period of approximately 3 months (days 1 to 99), an end-of-therapy visit, a
follow-up period (days 100 to 183), and an end-of-study visit approximately 3.5 months after the final
dose.
The study consisted of two cohorts. Cohort 1 (single arm and noncontrolled) was designed to
evaluate the PK of CSJ148 in transplant recipients. Six patients were enrolled in cohort 1; all received i.v.
CSJ148 every 28 days for the duration of the treatment period (99 days). Cohort 2 was randomized,
double blinded, and placebo controlled. The 80 patients enrolled in cohort 2 were randomized to CSJ148
or placebo in a 3:1 ratio, with dosing every 28 days (days 1, 29, 57, and 85). For all patients who received
CSJ148 in either cohort, the doses consisted of 50 mg/kg of body weight LJP538 infused i.v. over 2 h and
5 mg/kg LJP539 infused over 0.2 h. The Institutional Review Board (IRB) or ethics committees approved
the study protocol and all amendments. All subjects provided written informed consent.
Patients. Eligible patients were males and females 18 years of age undergoing allogeneic HCT of
all types (myeloablative or reduced-intensity conditioning using related, unrelated, or haploidentical
donors) and for any indication. All the patients were required to be HCMV seropositive before trans-
plantation. Key exclusion criteria included HCMV-related organ disease within 6 months of enrollment,
detectable HCMV infection (determined by positive pp65 antigenemia or plasma HCMV DNA PCR at local
laboratories) within 14 days prior to enrollment, or use of any medications with anti-HCMV activity within
30 days prior to enrollment. Patients were also excluded if they had a history of hypersensitivity to
monoclonal antibodies, impaired renal function requiring dialysis, severe liver disease, or any surgical or
medical condition that might increase the risk for thrombotic events (including cryoglobulinemia,
monoclonal gammopathies, and severe hypertriglyceridemia).
Trial assessments. Efficacy was assessed through monitoring of both HCMV loads and clinical
outcomes, including the development of HCMV disease and the use of rescue medication to treat HCMV
(based on the need for preemptive therapy or therapy for HCMV disease). The primary efficacy endpoint
was the proportion of patients who required preemptive anti-HCMV therapy based on a plasma HCMV
DNA of 1,000 copies/ml (based on central-laboratory results) or who developed HCMV disease within
99 days after the start of dosing. HCMV loads were monitored weekly during the treatment period.
Secondary endpoints included the time to start and duration of preemptive therapy, the number of
preemptive therapy courses required, and the proportion of patients developing HCMV disease, as
defined in published criteria (29) and detailed in the supplemental material. Safety assessments consisted
Maertens et al. Antimicrobial Agents and Chemotherapy
April 2020 Volume 64 Issue 4 e02467-19 aac.asm.org 10
of collecting all adverse events and regular monitoring of hematology and blood and urine chemistry.
Blood samples for PK and CSJ148 immunogenicity (anti-drug antibodies) were collected throughout the
study and analyzed as previously described (10).
Statistical methods. This study was designed to determine if CSJ148 could prevent HCMV replica-
tion after HCT and therefore reduce the proportion of patients requiring preemptive anti-HCMV therapy
or developing HCMV disease. The analysis sets are described in Table 1, with exclusions outlined in the
supplemental material.
The safety (or full analysis) set included all patients who received at least one dose of the study drug.
The PK analysis set included patients in the full analysis set with available PK data and no protocol
deviations that could influence the results. The PD analysis set included patients from cohort 2 in the full
analysis set with available PD data and no protocol deviations that could impact the results, such as
missing any dose of the study drug, use of medications with anti-HCMV activity when the primary
endpoint was not met, and non-HCMV-related death. Additional PD analyses included all the patients in
cohorts 1 and 2 who met the criteria for the first PD analysis set and patients who received anti-HCMV
medications who were otherwise eligible for the PD analysis sets (modified PD).
The primary endpoint was summarized with descriptive statistics by cohort and treatment arm. For
cohort 2, the primary endpoint was modeled with the binomial distribution for the event probabilities
for the treatment arm (pT) and the control arm (pC). The pT was given by a noninformative beta prior
distribution with parameters 1/3 and 1/3. A Bayesian analysis with an informative prior for the control
arm was applied to the full analysis set. The pC was given by an informative prior (based on a
meta-analysis conducted on historical studies with similar designs). The informative prior was a mixture
of three beta distributions with parameters equal to 19.49 and 28.80 (first beta component), 3.88 and 5.11
(second beta component), and 1 and 1 (third beta component). The mixture weights were 0.64, 0.31, and
0.05, respectively. Based on these priors and the observed primary outcome of this study, posterior
distributions for pT and pC were computed. These posterior distributions were summarized by the
posterior medians and standard deviations. Ninety percent credible intervals were also provided.
The posterior distribution for pT/pC (the risk ratio) was computed and summarized in a similar
fashion. Additionally, posterior probabilities (confidence levels) that the risk ratio was 1 and 0.5 were
computed.
Exploratory post hoc subgroup analyses to assess the effects of potential confounding factors based
on baseline and postenrollment factors on patients requiring preemptive HCMV therapy were performed
as needed. Tests of associations between potential confounding factors and primary outcomes adjusting
for treatment were performed using a CMH test, while Fisher’s exact test was used to test for associations
between potential confounding factors and treatment. Since the small sample size limited the power to
identify associations, we considered P values of 0.30 as potential signals of association, with the caveat
of a high false-positive rate (3 in 10 chances of falsely rejecting the null hypothesis of no association).
Safety endpoints were summarized using descriptive statistics. Secondary and exploratory analyses
included time to start and duration of preemptive therapy, number of preemptive therapy courses
required, HCMV load at the start of preemptive therapy, and the proportion of patients developing HCMV
disease.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 0.2 MB.
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